+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
HALEOSLABS

Haleos Labs Share Price

 

 

Haleos Labs live price: ₹1596.6. It opened at ₹1,546 vs previous close ₹1,547; intraday high/low: ₹1,644/₹1,540. The 50 & 200 DMA stand at ₹1,478.87/₹1,354.33.

Haleos Labs Performance

  • Today's Low
  • ₹1,540
  • Today's High
  • ₹1,644
  • 52 Week Low
  • ₹1,067
  • 52 Week High
  • ₹1,774
  • Open Price₹1,546
  • Previous Close₹1,547
  • Volume2,403
  • 50 DMA₹1,478.87
  • 100 DMA₹1,424.02
  • 200 DMA₹1,354.33

Haleos Labs Chart

Investment Returns

  • Over 1 Month + 13.79%
  • Over 3 Month + 24.03%
  • Over 6 Month + 23.43%
  • Over 1 Year + 37.98%

Smart Investing Starts Here Start SIP with Haleos Labs for Steady Growth!

Invest Now

Haleos Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27.9
  • PEG Ratio
  • -2
  • Market Cap Cr
  • 483
  • P/B Ratio
  • 2.3
  • Average True Range
  • 93.49
  • EPS
  • 57.26
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 22.25
  • RSI
  • 58.45
  • MFI
  • 86.95

Haleos Labs Financials

Haleos Labs Technicals

EMA & SMA

Current Price
₹1,596.60
+ 49.8 (3.22%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,521.20
  • 50 Day
  • ₹1,478.90
  • 100 Day
  • ₹1,424.00
  • 200 Day
  • ₹1,354.30

Resistance and Support

1593.53 Pivot Speed
  • R3 1,751.07
  • R2 1,697.53
  • R1 1,647.07
  • S1 1,543.07
  • S2 1,489.53
  • S3 1,439.07

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Haleos Labs Ltd has an operating revenue of Rs. 333.79 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of 8% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 17% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 47 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Haleos Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results & Final Dividend
2026-02-11 Quarterly Results
2025-11-10 Quarterly Results
2025-08-11 Quarterly Results & A.G.M.
2025-05-29 Audited Results & Dividend
Date Purpose Remarks
2025-09-24 FINAL Rs.1.50 per share(15%)Dividend
View Haleos Labs Dividend History Arrow

Haleos Labs Shareholding Pattern

72.11%
23.99%
3.9%

Haleos Labs FAQs

Haleos Labs share price is ₹1,596 As on 12 July, 2026 | 23:35

The Market Cap of Haleos Labs is ₹482.7 Cr As on 12 July, 2026 | 23:35

The P/E ratio of Haleos Labs is 27.9 As on 12 July, 2026 | 23:35

The PB ratio of Haleos Labs is 2.3 As on 12 July, 2026 | 23:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23